Biomarkers Could Predict Bladder Cancer Progression

NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

Phase 2b SunRISe-1 trial findings supported the FDA to grant priority review to TAR-200 in BCG-unresponsive high-risk NMIBC with carcinoma in situ.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Petros Grivas, MD, PhD;David Morris, MD, MS

AI-Based Urine Test Earns FDA Breakthrough Device Status in Bladder Cancer

The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.

Use of the novel artificial intelligence–based test may provide a painless, low-cost alternative in bladder cancer screening.

Oncology Peer Review On-The-Go: Neoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder Cancer

Use of the novel artificial intelligence–based test may provide a painless, low-cost alternative in bladder cancer screening.

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

Matthew Fowler;Jun Gong, MD

FDA Approves Mitomycin Solution in Low-Grade Intermediate-Risk NMIBC

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

Data from the phase 3 ENVISION trial support the FDA approval of the mitomycin solution for patients with recurrent, low-grade, intermediate-risk NMIBC.

Robust Responses Occur With UGN-102 in Recurrent Intermediate-Risk NMIBC

Data from the phase 3 ENVISION trial support the FDA approval of the mitomycin solution for patients with recurrent, low-grade, intermediate-risk NMIBC.

Data from the ENVISION trial may support UGN-102 as a well-tolerated, efficacious treatment in non–muscle-invasive bladder cancer.

Gina Mauro

FDA Grants Priority Review to TAR-200 in BCG-Unresponsive High-Risk NMIBC

Data from the ENVISION trial may support UGN-102 as a well-tolerated, efficacious treatment in non–muscle-invasive bladder cancer.

Related Content

Ariana Pelosci

NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

Phase 2b SunRISe-1 trial findings supported the FDA to grant priority review to TAR-200 in BCG-unresponsive high-risk NMIBC with carcinoma in situ.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Petros Grivas, MD, PhD;David Morris, MD, MS

AI-Based Urine Test Earns FDA Breakthrough Device Status in Bladder Cancer

The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.

Oncology Peer Review On-The-Go: Neoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder Cancer

Use of the novel artificial intelligence–based test may provide a painless, low-cost alternative in bladder cancer screening.

Matthew Fowler;Jun Gong, MD

FDA Approves Mitomycin Solution in Low-Grade Intermediate-Risk NMIBC

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

Robust Responses Occur With UGN-102 in Recurrent Intermediate-Risk NMIBC

Data from the phase 3 ENVISION trial support the FDA approval of the mitomycin solution for patients with recurrent, low-grade, intermediate-risk NMIBC.

Gina Mauro